Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)

Market Cap	27.05B
Revenue (ttm)	5.53B
Net Income (ttm)	1.34B
Shares Out	2.23B
EPS (ttm)	0.60
PE Ratio	20.21
Forward PE	17.45
Dividend	0.27 (2.17%)
Ex-Dividend Date	Jun 10, 2025

Volume	29,268,020
Average Volume	31,550,486
Open	12.33
Previous Close	12.35
Day's Range	12.11 - 12.36
52-Week Range	10.41 - 16.58
Beta	0.16
RSI	43.39
Earnings Date	Aug 26, 2025

About SHE:301301

Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. The company offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; urso...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3,184
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301301

Financial Performance

In 2024, SHE:301301's revenue was 5.76 billion, an increase of 19.38% compared to the previous year's 4.82 billion. Earnings were 1.40 billion, an increase of 48.88%.